Biotech Destiny Pharma Tips Into Insolvency in Cash Crisis – BNN Bloomberg
(Bloomberg) — Destiny Pharma Plc, a British biotech company chaired by City veteran Nigel Rudd, has appointed insolvency practitioners after failing to secure a rescue deal. Destiny Pharma, which earlier this month delisted from the London Stock Exchange’s Alternative Investment Market, had been unable to secure a licensing partner to fund clinical trials for its…










